Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

Exclusion Criteria

• •If a patient has any of the following conditions should not be included in this study:
• •1. Known allergy to the active ingredients or excipients of linperlisib and CHOP regimens.
• •2. Patients with factors that affect oral medications (such as inability to swallow, chronic diarrhea, and intestinal obstruction);
• •3. Medical History and comorbidity
• •1. The subject had any active, known, or suspected autoimmune disease. Subjects who are in a stable state and do not require systemic immunosuppressive therapy are admitted;
• •2. Known history of interstitial pneumonia;
• •3. Current or previous history of other malignancies within 2 years prior to study enrollment.Radically treated basal cell carcinoma of the skin, papillary thyroid carcinoma, squamous skin carcinoma, carcinoma in situ of the breast and carcinoma in situ of the cervix, excepted
• •4. Received systemic antitumor therapy, including chemotherapy, immunotherapy, and biotherapy (tumor vaccines, cytokines, or growth factors used to control cancer) within 28 days prior to study enrollment.
• •5. Received autologous or allogeneic hematopoietic stem cell transplantation;
• •6. Patients with active tuberculosis (TB) should be excluded.
• •7. Severe acute or chronic infections requiring systemic treatment;
• •8. Patients with hypertension that is not well controlled with antihypertensive medications (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg)
• •9. Poor diabetes control (fasting blood glucose (FBG) \> 10mmol/L);
• •10. Patients with heart failure (New York Heart Association standard Class III or IV), poor coronary artery disease control or arrhythmia, or a history of myocardial infarction within the 6 months prior to screening despite receiving appropriate medication;
• •11. Had clinically significant bleeding symptoms or definite bleeding tendency within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, stool occult blood ++ or above at baseline, or vasculitis;
• •12. Renal failure requiring hemodialysis or peritoneal dialysis;
• •13. Urine routine indicated urinary protein ≥++, and 24-hour urinary protein quantity \> 1.0 g；
• •14. Patients who have had major surgery or severe trauma have had the effects of the surgery or trauma resolved for less than 28 days prior to enrollment；
• •15. Complicated interstitial lung disease or history of severely impaired lung function;
• •16. Patients requiring systemic therapy with corticosteroids (\> 10 mg/day of prednisone or equivalent) or other immunosuppressive agents within 14 days prior to administration of study drug. Inhaled or topical steroids and adrenal hormone replacement at doses \> 10 mg/day prednisone efficacy dose are allowed in the absence of active autoimmune disease;
• •4. Physical and laboratory findings
• •1. A known history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive).
• •2. Active hepatitis \[Hepatitis B: Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive and ALT above the upper limit of detection; Hepatitis C: Hepatitis C virus (HCV) ribonucleic acid (RNA) positive and ALT above the upper limit of detection\]; co-infection with Hepatitis B and Hepatitis C;
• •5. Any medical history or disease evidence that may interfere with the study results or other conditions that investigators consider inappropriate for the study.
• •6. Pregnant or lactating women.